All In Biotech

Drug Trial Radar · NCT00004196

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

A Multicenter Trial of Adjuvant Interferon Alfa-2b for Melanoma Patients With Early Lymph Node Metastasis Detected by Lymphatic Mapping and Sentinel Lymph Node Biopsy

Last checked: Nov 20, 2026Latest source record: Jan 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,000

Planned (sponsor's estimate)

Start

Oct 1999

Primary completion

Oct 2004

Study completion Nov 2007

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node metastasis.

Conditions

  • Melanoma (Skin)

Interventions

  • recombinant interferon alfaBiological

  • lymphangiographyProcedure

  • ObservationDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Comprehensive Cancer Center

    Birmingham, Alabama

  • James Graham Brown Cancer Center at University of Louisville

    Louisville, Kentucky

  • Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.